Consensus or Controversy: Clinical Investigators Provide Perspectives on Targeted Treatment of Non-Small Cell Lung CancerConsensus or Controversy: Clinical Investigators Provide Perspectives on Targeted Treatment of Non-Small Cell Lung Cancer
Second-line therapy for patient with ROS1 rearrangement after progression on crizotinib?
1:00 minutes. |